Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer.

Saylor PJ, Smith MR, O'Malley AJ, Keating NL.

Eur Urol. 2014 Mar;65(3):642-9. doi: 10.1016/j.eururo.2013.02.003.

2.

Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.

Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, Shariat SF, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI.

Eur Urol. 2014 Dec;66(6):1125-32. doi: 10.1016/j.eururo.2014.01.026.

PMID:
24495466
3.

Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.

Hu JC, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NL.

Eur Urol. 2012 Jun;61(6):1119-28. doi: 10.1016/j.eururo.2012.01.045.

4.

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Keating NL, O'Malley AJ, Freedland SJ, Smith MR.

J Natl Cancer Inst. 2010 Jan 6;102(1):39-46. doi: 10.1093/jnci/djp404. Erratum in: J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23.

5.

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

Keating NL, O'Malley AJ, Smith MR.

J Clin Oncol. 2006 Sep 20;24(27):4448-56.

PMID:
16983113
6.

Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.

Sun M, Choueiri TK, Hamnvik OP, Preston MA, De Velasco G, Jiang W, Loeb S, Nguyen PL, Trinh QD.

JAMA Oncol. 2016 Apr;2(4):500-7. doi: 10.1001/jamaoncol.2015.4917.

PMID:
26720632
7.

Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.

Wu CT, Yang YH, Chen PC, Chen MF, Chen WC.

Osteoporos Int. 2015 Sep;26(9):2281-90. doi: 10.1007/s00198-015-3135-9.

PMID:
25990353
8.

The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.

Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, Trinh QD, Saad F, Graefen M, Briganti A, Montorsi F, Karakiewicz PI.

BJU Int. 2014 Dec;114(6b):E82-9. doi: 10.1111/bju.12732.

9.

Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.

Gillessen S, Templeton A, Marra G, Kuo YF, Valtorta E, Shahinian VB.

J Natl Cancer Inst. 2010 Dec 1;102(23):1760-70. doi: 10.1093/jnci/djq419.

10.

Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.

Lapi F, Azoulay L, Niazi MT, Yin H, Benayoun S, Suissa S.

JAMA. 2013 Jul 17;310(3):289-96. doi: 10.1001/jama.2013.8638.

PMID:
23860987
11.

Risk of new-onset diabetes after androgen deprivation therapy for prostate cancer in the Asian population.

Teoh JY, Chiu PK, Chan SY, Poon DM, Cheung HY, Hou SS, Ng CF.

J Diabetes. 2015 Sep;7(5):672-80. doi: 10.1111/1753-0407.12226.

PMID:
25266491
12.

Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.

O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M.

J Clin Oncol. 2015 Apr 10;33(11):1243-51. doi: 10.1200/JCO.2014.59.1792.

PMID:
25732167
13.

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.

Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS.

Cancer. 2005 Apr 15;103(8):1615-24. Review.

14.

Androgen deprivation and thromboembolic events in men with prostate cancer.

Ehdaie B, Atoria CL, Gupta A, Feifer A, Lowrance WT, Morris MJ, Scardino PT, Eastham JA, Elkin EB.

Cancer. 2012 Jul 1;118(13):3397-406. doi: 10.1002/cncr.26623.

15.

Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.

Shao YH, Moore DF, Shih W, Lin Y, Jang TL, Lu-Yao GL.

BJU Int. 2013 May;111(5):745-52. doi: 10.1111/j.1464-410X.2012.11758.x.

16.

Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer.

Azoulay L, Yin H, Benayoun S, Renoux C, Boivin JF, Suissa S.

Eur Urol. 2011 Dec;60(6):1244-50. doi: 10.1016/j.eururo.2011.08.041.

PMID:
21908097
17.

Androgen deprivation therapy and cataract incidence among elderly prostate cancer patients in the United States.

Beebe-Dimmer J, Morgenstern H, Cetin K, Yee C, Bartoces M, Shahinian V, Fryzek J, Acquavella J, Schwartz KL.

Ann Epidemiol. 2011 Mar;21(3):156-63. doi: 10.1016/j.annepidem.2010.10.003.

18.

Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden.

Thorstenson A, Bratt O, Akre O, Hellborg H, Holmberg L, Lambe M, Bill-Axelson A, Stattin P, Adolfsson J.

Eur J Cancer. 2012 Jul;48(11):1672-81. doi: 10.1016/j.ejca.2012.01.035.

PMID:
22386317
19.

Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.

Carson AP, Howard DL, Carpenter WR, Taylor YJ, Peacock S, Schenck AP, Godley PA.

J Pain Symptom Manage. 2010 May;39(5):872-81. doi: 10.1016/j.jpainsymman.2009.09.013.

20.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators..

Cancer. 2006 Apr 15;106(8):1708-14.

Items per page

Supplemental Content

Support Center